Dr. Deirdre Cohen on When to Treat Gastric Cancer Patients With Immunotherapies
Dr. Deirdre Cohen talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers.
Deirdre Cohen, MD, assistant professor of medicine, NYU Langone's Laura and Isaac Perlmutter Cancer Center, talks about the increasingly big role of immunotherapies in the treatment of patients with gastric cancers. Cohen says single agents used in patients with the subtype of gastric cancer that show higher levels of PD-L1 and PD-L2 expression, will most likely get the most benefit out of treatment.
Cohen adds that immunotherpies used in conjunction with other agents are more likely to be useful in the treatment of other types of gastric cancer outside those showcasing PD-L1 and PD-L2 expression. She also notes that according to the TCGA classifications, there are four subtypes of gastric cancers.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
